The associations between small vessel disease (SVD) and cerebrospinal amyloid-β1-42 (Aβ1-42) pathology have not been well-elucidated.
Objective:
Baseline (BL) white matter hyperintensities (WMH) were examined for associations with month-24 (M24) and longitudinal Aβ1-42 change in cognitively normal (CN) subjects. The interaction of WMH and Aβ1-42 on memory and executive function were also examined.
Methods:
This study included 72 subjects from the Alzheimer’s Disease Neuroimaging Initiative. Multivariable linear regression models evaluated associations between baseline WMH/intracranial volume ratio, M24 and change in Aβ1-42 over two years. Linear mixed effects models evaluated interactions between BL WMH/ICV and Aβ1-42 on memory and executive function.
Results:
Mean age of the subjects (Nmales = 36) = 73.80 years, SD = 6.73; mean education years = 17.1, SD = 2.4. BL WMH was significantly associated with M24 Aβ1-42 (p = 0.008) and two-year change in Aβ1-42 (p = 0.006). Interaction between higher WMH and lower Aβ1-42 at baseline was significantly associated with worse memory at baseline and M24 (p = 0.003).
Conclusion:
BL WMH was associated with M24 and longitudinal Aβ1-42 change in CN. The interaction between higher WMH and lower Aβ1-42 was associated with poorer memory. Since SVD is associated with longitudinal Aβ1-42 pathology, and the interaction of both factors is linked to poorer cognitive outcomes, the mitigation of SVD may be correlated with reduced amyloid pathology and milder cognitive deterioration in Alzheimer’s disease.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
ThalLJ, KantarciK, ReimanEM, KlunkWE, WeinerMW, ZetterbergH, GalaskoD, PraticòD, GriffinS, SchenkD, SiemersE (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord20, 6–15.
4.
KurzA, RiemenschneiderM, WallinA (2003) Potential biological markers for cerebrovascular disease. Int PsychogeriatrSuppl 1, 89–97.
5.
ChenC, HommaA, MokVC, KrishnamoorthyE, AlladiS, MeguroK, AbeK, DominguezJ, MarasiganS, KandiahN, KimSY, LeeDY, De SilvaHA, YangYH, PaiMC, SenanarongV, DashA (2016) Alzheimer’s disease with cerebrovascular disease: Current status in the Asia-Pacific region. J Intern Med280, 359–374.
6.
WhiteL, SmallBJ, PetrovitchH, RossGW, MasakiK, AbbottRD, HardmanJ, DavisD, NelsonJ, MarkesberyW (2005) Recent clinical-pathologic research on the causes of dementia in late life: Update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol18, 224–227.
7.
KalariaRN, AkinyemiR, IharaM (2012) Does vascular pathology contribute to Alzheimer changes?J Neurol Sci322, 141–147.
8.
PrinsND, van DijkEJ, den HeijerT, VermeerSE, KoudstaalPJ, OudkerkM, HofmanA, BretelerMM (2004) Cerebral white matter lesions and the risk of dementia. Arch Neurol61, 1531–1534.
9.
WardlawJM, Valdés HernándezMC, Muñoz-ManiegaS (2015) What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc4, 001140. Erratum in: J Am Heart Assoc5, e002006.
10.
PrinsN, ScheltensP (2015) White matter hyperintensities, cognitive impairment and dementia: An update. Nat Rev Neurol11, 157–165.
11.
GouwAA, SeewannA, van der FlierWM, BarkhofF, RozemullerAM, ScheltensP, GeurtsJJ (2011) Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry82, 126–135.
12.
LongstrethWTJr, BernickC, ManolioTA, BryanN, JungreisCA, PriceTR (1998) Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: The Cardiovascular Health Study. Arch Neurol55, 1217–1225.
13.
DufouilC, GodinO, ChalmersJ, CoskunO, MacMahonS, Tzourio-MazoyerN, BousserMG, AndersonC, MazoyerB, TzourioC; PROGRESS MRI Substudy Investigators (2009) Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke40, 2219–2221.
SoldanA, PettigrewC, ZhuY, WangMC, MoghekarA, GottesmanRF, SinghB, MartinezO, FletcherE, DeCarliC, AlbertM; BIOCARD Research Team (2020) White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. Neurology94, e950–e960.
20.
Graff-RadfordJ, Arenaza-UrquijoEM, KnopmanDS, SchwarzCG, BrownRD, RabinsteinAA, GunterJL, SenjemML, PrzybelskiSA, LesnickT, WardC, MielkeMM, LoweVJ, PetersenRC, KremersWK, KantarciK, JackCR, VemuriP (2019) White matter hyperintensities: Relationship to amyloid and tau burden. Brain142, 2483–2491.
21.
HanJW, MaillardP, HarveyD, FletcherE, MartinezO, JohnsonDK, OlichneyJM, FariasST, VilleneuveS, JagustW, MungasD, DeCarliC (2020) Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. Neurology95, e2622–e2634.
22.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
23.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
24.
DeCarliC, FletcherE, RameyV, HarveyD, JagustWJ (2005) Anatomical mapping of white matter hyperintensities (WMH): Exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke36, 50–55.
25.
KandelBM, AvantsBB, GeeJC, McMillanCT, ErusG, DoshiJ, DavatzikosC, WolkDA (2016) White matter hyperintensities are more highly associated with preclinical Alzheimer’s disease than imaging and cognitive markers of neurodegeneration. Alzheimers Dement (Amst)4, 18–27.
26.
OlssonA, VandersticheleH, AndreasenN, De MeyerG, WallinA, HolmbergB, RosengrenL, VanmechelenE, BlennowK (2005) Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem51, 336–345.
GordonBA, NajmiS, HsuP, RoeCM, MorrisJC, BenzingerTL (2015) The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. Neuroimage Clin8, 246–252.
29.
LowA, NgKP, ChanderRJ, WongB, KandiahN (2019) Association of asymmetrical white matter hyperintensities and Apolipoprotein E4 on cognitive impairment. J Alzheimers Dis70, 953–964.
IadecolaC (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol120, 287–296.
34.
SchneiderJA, WilsonRS, BieniasJL, EvansDA, BennettDA (2004) Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology62, 1148–1155.
35.
LazarusR, PrettymanR, CherrymanG (2005) White matter lesions on magnetic resonance imaging and their relationship with vascular risk factors in memory clinic attenders. . Int J Geriatr Psychiatry20, 274–279.
36.
Longstreth WTJr, ArnoldAM, BeauchampNJJr, ManolioTA, LefkowitzD, JungreisC, HirschCH, O’LearyDH, FurbergCD (2005) Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: The Cardiovascular Health Study. Stroke36, 56–61.
37.
FernandoMS, SimpsonJE, MatthewsF, BrayneC, LewisCE, BarberR, KalariaRN, ForsterG, EstevesF, WhartonSB, ShawPJ, O’BrienJT, IncePG; MRC Cognitive Function and Ageing Neuropathology Study Group (2006) White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. Stroke37, 1391–1398.
38.
FazekasF, KleinertR, OffenbacherH, SchmidtR, KleinertG, PayerF, RadnerH, LechnerH (1993) Pathologic correlates of incidental MRI white matter signal hyperintensities. . Neurology43, 1683–1689.
39.
EnzingerC, SmithS, FazekasF, DrevinG, RopeleS, NicholsT, BehrensT, SchmidtR, MatthewsPM (2006) Lesion probability maps of white matter hyperintensities in elderly individuals: Results of the Austrian stroke prevention study. J Neurol253, 1064–1070.
40.
WeaverNA, DoevenT, BarkhofF, BiesbroekJM, GroeneveldON, KuijfHJ, PrinsND, ScheltensP, TeunissenCE, van der FlierWM, BiesselsGJ; TRACE-VCI study group (2019) Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Neurobiol Aging84, 225–234.
41.
PrasadK, WiryasaputraL, NgA, KandiahN (2011) White matter disease independently predicts progression from mild cognitive impairment to Alzheimer’s disease in a clinic cohort. Dement Geriatr Cogn Disord31, 431–434.
42.
IliffJJ, WangM, LiaoY, PloggBA, PengW, GundersenGA, BenvenisteH, VatesE, DeaneR, GoldmanSA, NagelhusEA, NedergaardM (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med4, 147ra111.
43.
NiwaK, PorterVA, KazamaK, CornfieldD, CarlsonGA, IadecolaC (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol281, H2417–2424.
44.
NiwaK, CarlsonGA, IadecolaC (2000) . Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab20, 1659–1668.
45.
ParkL, AnratherJ, ForsterC, KazamaK, CarlsonGA, IadecolaC (2004) Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab24, 334–342.
46.
WestmanE, SimmonsA, MuehlboeckJS, MecocciP, VellasB, TsolakiM, KłoszewskaI, SoininenH, WeinerMW, LovestoneS, SpengerC, WahlundLO; AddNeuroMed consortium; Alzheimer’s Disease Neuroimaging Initiative (2011) AddNeuroMed and ADNI: Similar patterns of Alzheimer’s atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage58, 818–828.
47.
RothAD, RamírezG, AlarcónR, Von BernhardiR (2005) Oligodendrocytes damage in Alzheimer’s disease: Beta amyloid toxicity and inflammation. Biol Res38, 381–387.
48.
GurolME, IrizarryMC, SmithEE, RajuS, Diaz-ArrastiaR, BottiglieriT, RosandJ, GrowdonJH, GreenbergSM (2006) Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology66, 23–29.
49.
HeddenT, MorminoEC, AmariglioRE, YoungerAP, SchultzAP, BeckerJA, BucknerRL, JohnsonKA, SperlingRA, RentzDM (2012) Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci32, 16233–16242.
50.
KlunkWE (2011) Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging32 Suppl 1, S20–S36.
51.
HeddenT, Van DijkKR, BeckerJA, MehtaA, SperlingRA, JohnsonKA, BucknerRL (2009) Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci29, 12686–12694.
52.
SperlingRA, LaviolettePS, O’KeefeK, O’BrienJ, RentzDM, PihlajamakiM, MarshallG, HymanBT, SelkoeDJ, HeddenT, BucknerRL, BeckerJA, JohnsonKA (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron63, 178–188.
53.
VlassenkoAG, VaishnaviSN, CoutureL, SaccoD, ShannonBJ, MachRH, MorrisJC, RaichleME, MintunMA (2010) Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ) deposition. Proc Natl Acad Sci U S A107, 17763–17767.
54.
de GrootJC, de LeeuwFE, OudkerkM, van GijnJ, HofmanA, JollesJ, BretelerMM (2000) Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol47, 145–151.
55.
LongstrethWTJr, ManolioTA, ArnoldA, BurkeGL, BryanN, JungreisCA, EnrightPL, O’LearyD, FriedL (1996) Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke27, 1274–1282.
56.
Brugulat-SerratA, SalvadóG, SudreCH, Grau-RiveraO, Suárez-CalvetM, FalconC, Sánchez-BenavidesG, GramuntN, FauriaK, CardosoMJ, BarkhofF, MolinuevoJL, GispertJD; ALFA Study (2020) Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. Brain Imaging Behav14, 2012–2023.
57.
VannorsdallTD, WaldsteinSR, KrautM, PearlsonGD, SchretlenDJ (2009) White matter abnormalities and cognition in a community sample. Arch Clin Neuropsychol24, 209–217.
58.
KandiahN, NarasimhaluK, LeeJ, ChenCL (2009) Differences exist in the cognitive profile of mild Alzheimer’s disease and subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord27, 399–403.
59.
KimKW, MacFallJR, PayneME (2008) Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry64, 273–280.
60.
CharltonRA, BarrickTR, LawesIN, MarkusHS, MorrisRG (2010) White matter pathways associated with working memory in normal aging. Cortex46, 474–489.
61.
OostermanJM, Van HartenB, WeinsteinHC, ScheltensP, SergeantJA, ScherderEJ (2008) White matter hyperintensities and working memory: An explorative study. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn15, 384–399.
62.
HeddenT, Van DijkKR, ShireEH, SperlingRA, JohnsonKA, BucknerRL (2012) Failure to modulate attentional control in advanced aging linked to white matter pathology. Cereb Cortex22, 1038–1051.
63.
VipinA, LokeYM, LiuS, HilalS, ShimHY, XuX, TanBY, VenketasubramanianN, ChenCL, ZhouJ (2018) Cerebrovascular disease influences functional and structural network connectivity in patients with amnestic mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther10, 82.
64.
LampeL, Kharabian-MasoulehS, KynastJ, ArelinK, SteeleCJ, LöfflerM, WitteAV, SchroeterML, VillringerA, BazinPL (2019) Lesion location matters: The relationships between white matter hyperintensities on cognition in the healthy elderly. J Cereb Blood Flow Metab39, 36–43.
